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Abstract 
Rationale. The value of microRNAs (miRNAs) as biomarkers has been addressed in various clinical 
contexts. Initial studies suggested that miRNAs, such as the brain-enriched miR-124-3p, might improve 
outcome prediction after out-of-hospital cardiac arrest. The aim of this study is to determine the prognostic 
value of miR-122-5p in a large cohort of comatose survivors of out-of-hospital cardiac arrest. 
Methods. We analyzed 590 patients from the Targeted Temperature Management trial (TTM-trial). 
Circulating levels of miR-122-5p were measured in serum samples obtained 48 hours after return of 
spontaneous circulation. The primary end-point was poor neurological outcome at 6 months evaluated by the 
cerebral performance category score. The secondary end-point was survival at the end of the trial.  
Results. Forty-eight percent of patients had a poor neurological outcome at 6 months and 43% were dead at 
the end of the trial. Levels of miR-122-5p were lower in patients with poor neurological outcome compared 
to patients with good neurological outcome (p<0.001), independently of targeted temperature management 
regimen. Levels of miR-122-5p were significant univariate predictors of neurological outcome (odds ratios 
(OR), 95% confidence intervals (CI): 0.71 [0.57-0.88]). In multivariable analyses, miR-122-5p was an 
independent predictor of neurological outcome and improved the predictive value of a clinical model 
including miR-124-3p (integrated discrimination improvement of 0.03 [0.02-0.04]). In Cox proportional 
hazards models, miR-122-5p was a significant predictor of survival at the end of the trial. 
Conclusion. Circulating levels of miR-122-5p improve the prediction of outcome after out-of-hospital 
cardiac arrest. 
Key words: microRNAs; biomarker; prognostic; cardiac arrest; neurological function. 
Introduction 
Cardiac arrest is a life-threatening condition with 
an overall poor prognosis. Mortality of patients 
admitted to the intensive care unit after 
out-of-hospital cardiac arrest is around fifty percent. 
While early in-hospital mortality is mainly due to 
hemodynamic failure, half of survivors after hospital 
discharge suffer irreversible neurological sequelae or 
die within a few months [1]. In addition, withdrawal 
of life-sustaining therapies in patients with presumed 
poor prognosis accounts for a significant number of 
in-hospital deaths [2, 3]. Decision to withdraw life 
assistance is a difficult task which necessitates 
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accurate prognostication tools such as pathologic 
patterns on electroencephalograms, neuroimaging, 
absent pupillary reflexes to light, and absent 
somatosensory evoked potentials [4-7]. 
Neuron-specific enolase (NSE) is recommended by 
current guidelines in multimodal strategies [8], and 
high serial levels afford the best prediction [9]. 
Continuous monitoring of bispectral index, an 
indicator of brain activity, has shown some promise in 
prognostication after cardiac arrest [10]. Combined 
assessment of bispectral index and the 
neuron-enriched S100 beta protein provided an added 
prognostic value over single parameters [11]. New 
biomarkers would be invaluable for improving risk 
stratification and allow healthcare to be adapted 
according to outcome, optimizing treatment to 
patients likely to survive while avoiding futile and 
costly resources to patients with irreversible 
neurological sequelae [12]. It would also provide 
relatives with information about outcome at an earlier 
stage, limiting uncertainty and distress. 
The biomarker value of circulating microRNAs 
(miRNAs) has been extensively studied since the 
discovery that these small non-coding RNA molecules 
regulating gene expression are present in the 
bloodstream [13]. MicroRNAs appear to have the 
potential to improve personalized healthcare of 
patients with heart disease [14]. A few studies have 
indicated that circulating miRNAs may predict 
outcome after cardiac arrest. In two small-scale 
studies, plasma levels of miR-122-5p and miR-124-3p 
were associated with neurological outcome and 
survival after cardiac arrest [15, 16]. MiR-122-5p is 
enriched in the liver and is involved in lipid 
metabolism, inhibiting fatty acid oxidation and 
promoting fatty acid and triglyceride biosynthesis 
[17]. MiR-122-5p is also involved in glucose 
homeostasis and is consistently present in the blood, 
hence its potential biomarker value for cardiovascular 
and metabolic diseases [18]. Accordingly, plasma 
levels of miR-122-5p were found to be increased in a 
porcine cardiogenic shock model [19]. Recent 
investigations identified miR-122-5p in other organs 
such as the kidney [20], aortic valves [21] and the 
myocardium of patients with severe aortic stenosis 
where it regulates fibrosis [22]. In a discovery phase 
with small RNA sequencing, we observed an 
association between circulating levels of miR-122-5p 
and outcome after cardiac arrest [23]. In vitro, 
miR-122-5p has been shown to be expressed in 
different cell types including hepatocytes, fibroblasts 
and neuronal cells [15, 22]. The predictive capacity of 
brain-enriched miR-124-3p, whose circulating levels 
reflect the extent of brain damage after cardiac arrest, 
was recently confirmed in the large Targeted 
Temperature Management trial (TTM trial) [23], a trial 
designed to address the potential benefit of targeted 
temperature management at 33°C vs. 36°C on 
outcome after out-of-hospital cardiac arrest [24].  
In the present sub-study of the TTM trial, we 
assessed the incremental value of miR-122-5p to 
predict neurological outcome and survival after 
cardiac arrest.  
Methods 
Patients 
Between November 2010 and July 2013, the 36 
recruiting centers of the TTM trial enrolled 939 
unconscious adult patients admitted to an intensive 
care unit after an out-of-hospital cardiac arrest of 
presumed cardiac cause. Patients were randomized to 
either targeted temperature management at 33°C or 
36°C. The trial has received ethical approval from 
each participating country. Informed consent was 
obtained from each participant or relatives, according 
to the legislation in each country, and in line with the 
declaration of Helsinki [25]. Detailed TTM trial 
design, protocol, statistical analysis, results and 
interpretation have been published [24, 26, 27]. The 
trial is registered at www.clinicaltrials.gov 
(NCT01020916). Of the 36 recruiting sites, 29 collected 
blood samples in a total of 700 patients. Blood samples 
were stored at the Integrated Biobank of Luxembourg 
in compliance with the International Society for 
Biological and Environmental Repositories Best 
Practices and with International Organization for 
Standards (ISO 9001:2008, 17025:2005 and NF 
S96-900:2011). 
The biomarker steering committee and steering 
group of the TTM trial approved this sub-study. 
Study end-points 
The primary endpoint used in the present 
sub-study was poor neurological outcome as 
determined by a cerebral performance category (CPC) 
score [28] at 6 months of 3, 4 or 5. A CPC score of 3 
indicates severe neurological sequelae, 4 indicates 
coma or vegetative state, and 5 indicates death. 
Patients with a CPC score of 1 or 2, indicating no or 
moderate neurological sequelae respectively, were 
considered as having a good outcome. Determination 
of CPC was achieved as described in the TTM trial 
protocol [26]. The secondary end-point considered in 
this sub-study was survival until the end of the trial. 
Assessment of miR-122-5p levels 
Circulating levels of miR-122-5p were measured 
in serum samples collected 48 hours after return of 
spontaneous circulation (ROSC), as described 
previously [23, 29] and in the online supplement 
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(Methods and Figure S1). Levels of miR-122-5p were 
normalized with Cel-miR-39 and are expressed as 
number of miR-122-5p copies per µL of serum. 
For a time-course experiment, levels of 
miR-122-5p were also measured in serum samples 
from a sub-group of 43 patients for whom samples 
were available at 24, 48 and 72 hours after cardiac 
arrest. 
Assessment of NSE levels 
Neuron-specific enolase (NSE) was assessed in 
serum samples collected 48 hours after ROSC. 
Measurements were performed in a core laboratory 6 
months after completion of the trial, as previously 
described [9]. 
Statistical analysis 
Demographic and clinical data 
Comparisons between two groups of continuous 
variables were performed using the Mann-Whitney 
test. Categorical variables were compared with the 
Chi-square test or the Fisher exact test. A P value 
<0.05 was considered statistically significant. 
Levels of miR-122-5p 
Comparisons of miR-122-5p levels between two 
groups of patients were performed using the 
Mann-Whitney test. Associations between miR-122-5p 
levels and co-morbidities were determined using 
logistic regression. Correlations between miR-122-5p 
levels and age were determined using the Spearman 
test on ranks. 
Prediction of neurological outcome 
Both univariable and multivariable analyses 
with logistic regression were conducted to assess the 
association between miR-122-5p after log10 
transformation and neurological outcome as 
determined by dichotomized CPC at 6 months: CPC 
1-2 being considered a good neurological outcome (0 
value) and CPC 3-5 being considered a poor 
neurological outcome (1 value). For univariable 
analyses, the association between miR-122-5p and 
neurological outcome was assessed using the area 
under the receiver operating characteristic (ROC) 
curve (AUC). Odds ratios (OR) and 95% confidence 
intervals [95% CI] were computed for an increase of 1 
unit for continuous variables, which were centered 
and scaled. Missing data were computed using 
10-fold multiple imputation. Prediction value of 
multivariable models was estimated using the Akaike 
information criterion (AIC). Lower AIC is indicative 
of better model fit. The statistical significance of the 
decrease in AIC was assessed using the likelihood 
ratio test. The AIC was chosen to assess the predictive 
value of models when consecutively adding variables 
(i.e. miR-122-5p) to a baseline clinical model since it is 
penalized by the number of variables entered in the 
model, contrarily to the AUC. This allows to avoid 
model over fitting by the multiplication of co-variates. 
The incremental predictive value of miR-122-5p to the 
baseline model that included demographic and 
cardiac arrest-related clinical parameters was 
evaluated by the decrease in AIC and the integrated 
discrimination improvement (IDI). 
Survival analyses 
Cox proportional hazards and Kaplan-Meier 
curves were analyzed to evaluate the association 
between miR-122-5p after log10 transformation with 
survival until the end of the trial. For Cox 
proportional hazards, the association between 
miR-122-5p and survival was evaluated after 
adjusting with clinical variables using 10-fold 
multiple imputation. For Kaplan-Meier analysis, 
miR-122-5p levels were divided in quartiles.  
Softwares 
Between-group comparisons were performed 
using the SigmaPlot v 12.3 software. Prediction and 
survival analyses were performed using the R 
statistical environment (3.2.2) with the packages 
pROC, lmtest, survival and Hmisc. 
Results 
Patients 
A study design flow-chart is displayed in the 
Online supplement (Figure S2). A total of 939 patients 
were enrolled in the TTM trial. Among the 36 
recruiting sites, 29 sites collected blood samples for 
sub-studies. In the present sub-study, we included 590 
patients who survived the first 24 hours after ROSC 
and who had blood samples available for miRNA 
assessment (=miRNA cohort). Serum blood samples 
obtained 48 hours after ROSC were used for 
miR-122-5p assessment. This time-point was chosen 
for consistency with past studies [11, 15, 23, 30] and 
because the predictive value of NSE was highest 48 
hours after cardiac arrest [9]. The miRNA cohort had 
comparable demographic and clinical characteristics 
to the entire TTM cohort, except that fewer patients 
from the miRNA cohort had a medical history of 
myocardial infarction (Table S1 in the Online 
supplement). 80 % of patients in the miRNA cohort 
were males and the median [range] age was 64 
(20-94). 307 (52%) patients had a good neurological 
outcome at 6 months (CPC scores 1-2) and 283 (48%) 
patients had a poor neurological outcome or died 
(CPC scores 3-5) (Table 1). Patients with a poor 
neurological outcome or who died within 6 months 
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after cardiac arrest were older, had more often 
co-morbidities and an initial non-shockable rhythm 
compared to patients with a good neurological 
outcome. Time from cardiac arrest to ROSC, initial 
serum lactate levels and the frequency of circulatory 
shock on admission were higher in patients with poor 
outcome (Table 1). 
Circulating levels of miR-122-5p according to 
targeted temperature 
Of the 590 patients enrolled in this study, 286 
(48%) were randomized to 33°C and 304 (52%) to 
36°C. 147 (51%) patients randomized to 33°C had a 
good outcome and 160 (53%) patients randomized to 
36°C had a good outcome (p=0.92). In the 33°C group, 
levels of miR-122-5p were moderately but 
significantly higher compared to the 36°C group 
(Figure 1A). 
 
 
 
 
 
 
 
 
 
Table 1. Demographic and clinical features of patients with good 
and poor neurological outcome within the miRNA cohort. 
Characteristic Good outcome  
(CPC 1-2, n=307) 
Poor outcome  
(CPC 3-5, n=283) 
P value 
Age, years 60 (20-90) 68 (35-94) <0.001 
Gender    
 Male 254 (82.7%) 219 (77.4%) 0.13 
Co-morbidities    
 Hypertension 100 (32.6%) 133 (47.0%) <0.001 
 Diabetes mellitus 31 (10.1%) 52 (18.4%) 0.006 
 Known IHD 62 (20.2%) 92 (32.5%) <0.001 
 Previous MI 45 (14.7%) 64 (22.6%) 0.02 
 Heart failure 7 (2.3%) 26 (9.2%) <0.001 
 COPD 16 (5.2%) 32 (11.3%) 0.01 
 Renal failure 1 (0.3%) 4 (1.4%) 0.32 
 Previous cerebral stroke 17 (5.5%) 30 (10.6%) 0.03 
 Alcohol abuse 7 (2.3%) 10 (3.5%) 0.50 
First monitored rhythm   <0.001 
 VF or non-perfusing VT 282 (91.9%) 193 (68.2%)  
 Asystole or PEA 17 (5.5%) 80 (28.3%)  
 ROSC after bystander 
defibrillation 
6 (2.0%) 2 (0.7%)  
 Unknown 2 (0.7%) 8 (2.8%)  
Witnessed arrest 280 (91.2%) 245 (86.6%) 0.10 
Bystander CPR 244 (79.5%) 187 (66.1%) <0.001 
Time from CA to ROSC, min 20 (0-111) 30 (0-170) <0.001 
Initial serum lactate (mmol/l) 4.7 (0.5-20) 6.5 (0.5-25)  <0.001 
Shock on admission 24 (7.8%) 48 (17.0%) 0.001 
Continuous characteristics are indicated as median (range) and categorical 
characteristics are indicated as number (frequency). CA: cardiac arrest; COPD: 
chronic obstructive pulmonary disease; CPR: cardio-pulmonary resuscitation; IHD: 
ischemic heart disease; MI: myocardial infarction; PEA: pulseless electric activity; 
ROSC: return of spontaneously circulation; VF: ventricular fibrillation; VT: 
ventricular tachycardia. 
 
 
Figure 1. Serum levels of miR-122-5p according to targeted temperature and neurological outcome. Levels of miR-122-5p were assessed 48 hours after ROSC using quantitative PCR in 590 
patients. (A) Comparisons of miR-122-5p levels between patients treated at 33°C and patients treated at 36°C. (B-D) Comparisons of miR-122-5p levels between patients with good (CPC 
1-2) and poor (CPC 3-5) neurological outcome, independently of targeted temperature (B), in patients treated at 33°C (C) and in patients treated at 36°C (D). Patient numbers are displayed 
in italics. Levels of miR-122-5p are expressed as copy numbers per µL of serum. Y axes are in log scale. The lower boundary of the boxes indicates the 25th percentile, the horizontal line within 
the box indicates the median, the higher boundary of the box indicates the 75th percentile, the error bars indicate the 90th and 10th percentiles, and individual dots represent outliers. 
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Circulating levels of miR-122-5p according to 
neurological outcome 
Levels of miR-122-5p were lower in patients with 
poor outcome compared to patients with good 
outcome (Figure 1B). The outlier with high levels of 
miR-122-5p in the good outcome group did not affect 
this difference, nor did it affect the prediction 
analyses, and was therefore kept in all subsequent 
analyses. The difference in miR-122-5p levels between 
patients with good and poor outcome was 
independent of targeted temperature regimen (Figure 
1C-D). Consequently, patients were not separated into 
targeted temperature regimen groups in subsequent 
analyses. 
Association between miR-122-5p levels, 
co-morbidities, age and gender 
Levels of miR-122-5p were inversely associated 
with chronic heart failure (OR 0.59 [0.35-0.99], n=33) 
and history of arrhythmias (OR 0.73 [0.54-0.99], n=99). 
No significant associations were detected with other 
co-morbidities listed in Table 1. No patient had 
cirrhosis. 
Levels of miR-122-5p were inversely correlated 
with age (r=-0.24, P<0.001; Figure S3 in the Online 
supplement), although this correlation was not 
significant (p=0.43) in linear regression analysis. 
Levels of miR-122-5p tended to be higher in males 
compared to females (median 4.6x105 copies/µL vs. 
2.7x105 copies/µL, respectively; p=0.08). 
Association between miR-122-5p and 
miR-124-3p levels 
Levels of miR-122-5p were positively correlated 
with the levels of miR-124-3p assessed previously [23] 
(r=0.35, p<0.001; Figure S4 in the Online supplement). 
Time-course of miR-122-5p levels after cardiac 
arrest 
Levels of miR-122-5p were assessed in a 
sub-group of 43 patients for whom serum samples 
were available at 24, 48 and 72 hours after cardiac 
arrest. Levels of miR-122-5p gradually decreased from 
24 hours to 72 hours after cardiac arrest, both in the 
good and poor outcome groups (Figure S5 in the 
Online supplement). 
Prediction of neurological outcome 
In univariable analyses, levels of miR-122-5p 
were associated with 6-month neurological outcome, 
as determined by dichotomized 6-month CPC (CPC 
1-2 vs CPC 3-5), with an AUC of 0.62, 95% CI 
[0.54-0.63] (Figure 2). Patients with lower levels of 
miR-122-5p were at high risk for a poor neurological 
outcome (OR [95% CI]: 0.71 [0.57-0.88]).  
 
Figure 2. Association between levels of miR-122-5p and neurological outcome. 
Circulating levels of miR-122-5p were assessed using quantitative PCR in serum 
samples collected 48 hours after ROSC in 590 patients. Association between 
miR-122-5p and neurological outcome assessed by dichotomized CPC at 6 
months (CPC 1-2 vs. CPC 3-5) was evaluated using logistic regression. ROC 
curve and AUC are shown. 
 
In multivariable analyses − including age, 
gender (male), time from cardiac arrest to ROSC, 
bystander cardiopulmonary resuscitation (CPR), first 
monitored rhythm (ROSC after defibrillation or 
ventricular tachycardia (VT)-ventricular fibrillation 
(VF)), circulatory shock on admission, initial serum 
lactate levels, NSE levels at 48h, targeted temperature 
regimen and miR-124-3p −, levels of miR-122-5p were 
independent predictors of neurological outcome (OR 
[95% CI]: 0.51 [0.37-0.68]; Figure 3A). Age, first 
monitored rhythm (VT-VF), NSE and miR-124-3p also 
had a significant predictive value. Of note, 
temperature regimen was not associated with 
neurological outcome, confirming previous data from 
the main TTM trial [24]. The model reached a 
specificity of 91% and a sensitivity of 77%. 
To evaluate the incremental predictive value of 
miR-122-5p, we calculated the AIC of models 
including the demographic and cardiac arrest-related 
variables described above (=baseline model), with or 
without miR-122-5p and miR-124-3p. Results are 
summarized in Table 2. Adding miR-124-3p to the 
baseline model resulted in a decrease of AIC from 471 
(baseline model) to 466 (p=0.01), but failed to reach 
statistical significant in terms of IDI (0.006 
[-0.001-0.013]), p=0.095, as previously reported [23]. 
Adding miR-122-5p to the baseline model resulted in 
a decrease of AIC from 471 to 463 (p=0.002) and 
provided an IDI of 0.016 [0.007-0.025], p=5.0x10-4. 
Addition of miR-122-5p to the baseline model with 
miR-124-3p decreased the AIC from 466 to 446 
(p<0.001) and provided an IDI of 0.03 [0.02-0.04], 
p=1.3x10-5. Furthermore, adding both miR-122-5p and 
miR-124-3p to the baseline model improved the 
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prediction (decrease of AIC from 471 to 446, p<0.001, 
and IDI of 0.04 [0.02-0.05], p=2.6x10-6. Overall, both 
miR-122-5p and miR-124-3p were necessary to reach 
the maximal predictive value.  
 
 
Figure 3. Multivariable analyses. Odds ratios (OR) and hazard ratios (HR) ± 
95% confidence intervals (95% CI) are displayed for the prediction of 6-month 
neurological outcome (A) and survival until the end of the trial (B) respectively. 
The following variables were included in the models: age, gender (male), time 
from cardiac arrest to ROSC, bystander cardiopulmonary resuscitation (CPR), 
first monitored rhythm (ROSC after defibrillation or ventricular tachycardia 
(VT)-ventricular fibrillation (VF)), circulatory shock on admission initial serum 
lactate levels, NSE levels at 48h, targeted temperature regimen, and miRNA 
levels. 
Prediction of survival 
Cox proportional hazards models and 
Kaplan-Meier curves were analyzed to assess the 
association between circulating levels of miR-122-3p 
and miR-124-3p measured 48 hours after ROSC and 
survival until the end of the trial. Longest follow-up 
time was 956 days after cardiac arrest, and median 
time from cardiac arrest to death was 7 days. 43% of 
patients were dead at the end of the trial. In Cox 
proportional hazards models including the same 
clinical and demographic parameters as used in 
logistic regression for the prediction of neurological 
outcome, lower levels of miR-122-5p and higher levels 
of miR-124-3p predicted a shorter survival (Figure 
3B). Age, first monitored rhythm (VT-VF), lactate and 
NSE were also significantly associated with survival. 
Targeted temperature regimen was not associated 
with survival, as previously reported [24]. In 
Kaplan-Meier analysis, patients within the lowest 
quartiles of miR-122-5p levels were at high risk of 
shorter survival (Figure 4). Overall, patients with low 
levels of miR-122-5p were at high risk of death. 
 
 
Figure 4. Survival analyses. Kaplan Meier curves show the survival of patients 
according to their circulating levels of miR-122-5p measured 48 hours after 
ROSC in 590 patients. Levels of miR-122-5p were divided into quartiles. Ranges 
of miR-122-5p values in number of copies per µL of serum are indicated for each 
quartile. P value of Log-Rank test is shown. 
 
Table 2. Incremental value of miR-122-5p to predict neurological outcome as assessed by 6-month CPC score. 
Models AIC P value IDI [95% CI] P value 
Baseline model 471 0.01 (vs. baseline)   
 + miR-124-3p 466 0.006 [-0.001-0.013] 0.09 
 + miR-122-5p 463 0.002 (vs. baseline) 0.016 [0.007-0.025] 5.0x10-4 
 * (vs. baseline + miR-124-3p) 0.010 [-0.004-0.023] 0.17 
 + miR-124-3p 
and miR-122-5p 
446 <0.001 (vs. baseline) 0.04 [0.02-0.05] 2.6x10-6 
 <0.001 (vs. baseline + miR-124-3p) 0.03 [0.02-0.04] 1.3x10-5 
The baseline model includes age, gender, bystander cardiopulmonary resuscitation (CPR), first monitored rhythm, time from cardiac arrest to ROSC, initial serum lactate 
levels, shock on admission, 48h-NSE, and targeted temperature regimen. Log10-transformed miRNA values were used in these analyses. AIC: Akaike information criteria. 
Lower AIC indicates a better predictive value. IDI: integrated discrimination improvement. 
* The comparison of AIC between the baseline models with miR-124-3p or miR-122-5p could not be performed with the likelihood ratio test because the two models are not 
nested (i.e. variables of the first model are not a subset of the variables of the second model and vice versa).
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Discussion 
The association between miRNAs and outcome 
after out-of-hospital cardiac arrest has been reported 
previously. Circulating levels of brain-enriched 
miR-124-3p were associated with outcome in a 
previous sub-study of the TTM-trial [23]. In the 
present study, we addressed the value of miR-122-5p 
to improve outcome prediction after cardiac arrest. 
We observed that miR-122-5p was an independent 
predictor of neurological outcome and survival after 
cardiac arrest and provided an incremental prognostic 
value. 
The selection of miR-122-5p was based on a 
previous study indicating that this miRNA is 
associated with outcome after cardiac arrest [15]. 
Surprisingly, we found in the present study an 
inverse association between miR-122-5p levels and the 
risk of poor outcome after cardiac arrest, while 
miR-122-5p was positively associated with poor 
neurological outcome and mortality in our previous 
study [15]. Several explanations might exist for this 
discrepancy. Two independent cohorts of patients 
with cardiac arrest were used in the past [15] and 
present study, which differed substantially with 
respect to their size and design (small monocentric 
cohort in the past study versus large multicenter 
cohort in the present study), but similar in relation to 
there being no apparent link between miR-122-5p 
levels and liver function. This is important 
considering that miR-122 is enriched in the liver. In 
the present study, miR-122-5p levels were neither 
associated with the presence of shock on admission, 
which induces multiple organ damage including the 
liver, nor with the liver sub-score of the sequential 
organ failure assessment score [31], which was 
calculated from the highest bilirubin level each day in 
the intensive care unit (not shown). Even though fine 
characterization of liver function was not performed 
in the TTM-trial, the inverse relationship between 
miR-122-5p levels and poor outcome does not support 
a confounding effect of underlying liver disease on 
the predictive value of miR-122-5p. 
The Predictive Safety Testing Consortium 
(PSTC) of the Safer and Faster Evidence-based 
Translation (SAFE-T) Consortium estimated the mean 
circulating levels of miR-122 as approximately 2000 
copies/µL in the normal population and the upper 
limit of normal to 13,000 copies/µL [32]. In our cohort 
of cardiac arrest patients, 77% of patients from the 
good outcome group had miR-122-5p levels above 
13,000 copies/µL while only 38% of patients from the 
poor outcome group had such elevated levels. 
Together with the lower levels of miR-122-5p in the 
poor outcome group compared to the good outcome 
group, this observation suggests that patients from 
the poor outcome group may not be able to increase 
their levels of miR-122-5p in response to injury. This 
needs further investigation.  
The inverse association with outcome between 
miR-122-5p and miR-124-3p most likely explains the 
ability of miR-122-5p to provide an incremental value 
to a prognostic model including miR-124-3p. The 
modest yet significant collinearity between the two 
miRNAs is not strong enough to prevent the 
incremental value of miR-122-5p. This strengthens the 
concept that panels of miRNAs with different 
function or reflecting different pathophysiology are 
likely to have added value. Such miRNA panels have 
been reported in the past to predict outcome after 
acute myocardial infarction [33]. Furthermore, a 
miR-122-5p/133b ratio has shown some value to 
predict the risk of developing major adverse events 
after acute myocardial infarction [34]. In the case of 
cardiac arrest, adding another brain-enriched miRNA 
to a model already including miR-124-3p would have 
a weak chance for providing an incremental 
predictive value. 
The inverse association between age and 
miR-122-5p may not merely be responsible for the 
association between miR-122-5p and outcome since, 
in multivariable analyses, miR-122-5p was an 
independent predictor in a model including age as a 
covariate. In addition, the correlation between age 
and miR-122-5p, even though significant, was weak 
(r=-0.24, P<0.001; Spearman test) and lost significance 
in linear regression. Therefore, despite its correlation 
with age, miR-122-5p still appears robust as an 
independent prognostic marker. 
This leads to the question of a potential 
functional link between circulating levels of 
miR-122-5p and outcome after cardiac arrest. 
MiR-122-5p is expressed in cultured brain cells [15] 
but, since it is inversely associated with a poor 
neurological outcome in the present study, this 
association may not be only explained by a release of 
miR-122-5p from dying neuronal cells, as it is believed 
to be the case for brain-enriched miR-124-3p. The 
inverse association between miR-122-5p and poor 
outcome is against a causal relationship between liver 
failure, circulating levels of miR-122-5p, and poor 
outcome. Even though miR-122-5p levels were shown 
to be decreased in patients with renal failure [35], the 
very low proportion of patients with renal failure in 
the present study is unable to account per se for the 
association between miR-122-5p and outcome after 
cardiac arrest. Overall, miR-122-5p levels were not 
associated with the different organ-specific sub-scores 
of the sequential organ failure assessment score (not 
shown). The decrease of miR-122-5p levels over the 3 
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days following cardiac arrest may indicate a depletion 
of liver miR-122-5p at an early stage after cardiac 
arrest. This would encourage addressing the 
prognostic value of miR-122-5p at admission or in the 
few hours after cardiac arrest. Being able to predict 
outcome at an early stage after cardiac arrest would 
be of high clinical interest. 
In both animal experiments [36] and in vitro 
investigations [37, 38], the use of targeted temperature 
management (therapeutic hypothermia) modified the 
expression levels of some miRNAs in the brain. In a 
cardiogenic shock model in pigs, hypothermia 
decreased the plasma levels of miR-122-5p [19]. We 
found that miR-122-5p levels were modestly higher in 
patients randomized to the 33°C-group compared to 
patients randomized to 36°C. This difference did not 
affect the association between miR-122-5p and 
neurological outcome, and targeted temperature 
management regimen was not associated with 
outcome in multivariable analyses. This is consistent 
with the absence of significant effect of targeted 
temperature management at 33°C compared to 36°C 
on neurological outcome observed in the main TTM 
trial [24]. 
The main finding of the present study is that 
miR-122-5p has an incremental prognostic value to a 
clinical model including the previously described 
miR-124-3p [23]. This is important since, in our 
previous study [23], miR-124-3p failed to reach a 
statistically significant effect on outcome prediction. 
The incremental value of miR-122-5p observed in the 
present study was demonstrated in multivariable 
analyses in which this miRNA increased model fit, as 
attested by a decrease of AIC, and improved patient 
classification, as attested by a significant IDI. As a 
reminder, the AIC was used to assess the predictive 
value of multivariable models instead of the AUC 
since it is penalized by the number of variables 
entered in the model, thus avoiding model over 
fitting. 
Our findings have important potential clinical 
implications. Identification of novel biomarkers of 
outcome after cardiac arrest is needed since current 
biomarkers lack specificity. These novel biomarkers, 
combined with previously characterized 
brain-derived proteins such as NSE [9] and S100 beta 
[39], as well as clinical and neurophysiologic 
examination, may aid in identification of patients at 
high risk of poor outcome. Diagnostic assays to 
measure miRNAs on a routine basis are being 
implemented [14]. These assays are sensitive, do not 
require a high volume of blood, can be multiplexed 
and automated, and may therefore be cost-effective. 
Presuming that the incremental value of miRNAs for 
outcome prediction after cardiac arrest can be 
confirmed in future large-scale studies, multiplex 
miRNA assays could be developed and used in 
multimodal prediction algorithms involving clinical 
examination, neurophysiologic tests and brain 
imaging. These miRNA assays could aid in 
personalizing healthcare, not only of patients with 
cardiac arrest, but also of patients with 
cerebrovascular diseases such as stroke. 
This study has a number of strengths and 
limitations. One strength is that it is a predefined 
sub-study of the largest prospective multicenter 
randomized clinical trial testing the benefit of two 
target temperature regimens in cardiac arrest patients. 
Blood samples used for biomarker determination 
were stored in a single biobank according to best 
practices and international standards. Furthermore, 
miR-122-5p assessment was performed in a single 
laboratory, thus allowing to maximize consistency of 
sample handling and processing. Measurement of 
miR-122-5p was performed according to extensively 
characterized and validated procedures. Levels of 
miR-122-5p are expressed as an absolute 
concentration (copy number per µL of serum), while 
the majority of past miRNA studies reported relative 
concentrations. Although it may be difficult to 
implement for weakly expressed miRNAs (which is 
not the case of miR-122-5p), the absolute 
quantification method has the advantage of allowing 
for comparisons of expression levels between 
different analytical platforms. One limitation relates 
to the selection of only one miRNA for this study, and 
it cannot be excluded that other miRNAs might have a 
further added prognostic value. In addition, this 
study was performed in a sub-group of patients of the 
TTM-trial for whom blood samples were available for 
biomarker studies. However, this sub-group had 
comparable demographic and clinical characteristics 
to the entire cohort. The evolution over time of 
miR-122-5p levels in the 3 days following cardiac 
arrest was performed in a small subgroup of patients 
and only miR-122-5p levels measured 48h after ROSC 
were used in prediction analyses. Further studies are 
warranted to determine the best time-points for 
optimal prediction, as well as the influence of renal 
function on the circulating levels of miRNAs such as 
miR-122-5p. Finally, a biologically plausible 
explanation for the inverse association between 
miR-122-5p levels and outcome remains to be 
established. 
In conclusion, we have shown that miR-122-5p is 
associated with neurological outcome and survival 
after cardiac arrest. Levels of miR-122-5p measured 48 
after ROSC provide an incremental predictive value 
and may constitute a novel biomarker to aid in 
outcome prediction after cardiac arrest. 
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